BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX) trades at $75.93. BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX) is a non-diversified fund focused on long-term capital growth through investments in health sciences and related industries. Market cap: $5.91B, Sector: Financial services.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for SHSKX: SHSKX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SHSKX against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SHSKX: 1/1 perspectives are bearish.
How is this calculated? →BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX) Financial Services Profile
BlackRock Health Sciences Opportunities Portfolio Class K is a specialized fund focusing on equity securities within the health sciences sector, including healthcare equipment, biotechnology, and pharmaceuticals. With a concentration strategy and global investment scope, SHSKX aims for long-term capital appreciation, operating with a beta of 0.66 and no dividend payouts.
What Is the Investment Thesis for SHSKX?
BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX) presents an investment opportunity centered on the long-term growth potential of the health sciences sector. The fund's concentrated investment approach, with at least 80% of its assets in health care equipment, biotechnology, and pharmaceuticals, allows it to capitalize on the sector's innovation and expansion. Key to the investment thesis is the aging global population and increasing demand for healthcare services. The fund's global investment scope offers diversification and access to international markets. However, investors should be aware of the fund's non-diversified nature, which can lead to higher volatility compared to broader market funds. The fund's beta of 0.66 suggests lower volatility than the overall market. The absence of dividend payouts means returns are solely dependent on capital appreciation.
Based on FMP financials and quantitative analysis
SHSKX Key Highlights
- Market capitalization of $5.91B, indicating a substantial presence in the asset management industry.
- Concentrated investment strategy with at least 80% of total assets allocated to equity securities in the health sciences sector.
- Focus on health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals.
- Global investment scope, including companies located in non-U.S. countries, providing diversification.
- Beta of 0.66, suggesting lower volatility compared to the broader market.
Who Are SHSKX's Competitors?
SHSKX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FSPHX Fidelity Select Health Care Portfolio | $28.19 | +1.73% | $5.78B | 46 |
| LMGNX ClearBridge International Growth I | $77.78 | +0.04% | $7.21B | 46 |
| PRPFX Permanent Portfolio Class I | $76.56 | +0.30% | $7.68B | 50 |
| RBAIX T. Rowe Price Balanced I Class | $29.81 | +0.40% | $5.34B | 44 |
| SHISX BlackRock Health Sciences Opportunities Portfolio Service Shares | $69.95 | +0.00% | $5.91B | 38 |
| NXDT NexPoint Diversified Real Estate Trust | $5.53 | +3.08% | $285.77M | 73 |
| GENB Generate Biomedicines, Inc. | $17.03 | -2.18% | $2.18B | 72 |
| SII Sprott Inc. | $118.11 | +2.72% | $3.05B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SHSKX's Key Strengths?
- Strong focus on the health sciences sector.
- Managed by BlackRock, a leading global asset manager.
- Potential for high growth due to the expanding healthcare industry.
- Global investment scope provides diversification.
What Are SHSKX's Weaknesses?
- Non-diversified fund, which can lead to higher volatility.
- Concentrated investment approach may increase risk.
- Performance is highly dependent on the health sciences sector.
- No dividend payouts, relying solely on capital appreciation.
What Could Drive SHSKX Stock Higher?
- Aging global population driving increased demand for healthcare services.
- Technological advancements and innovation in biotechnology and pharmaceuticals.
- Expansion of healthcare infrastructure in emerging markets.
- Potential regulatory approvals for new drugs and medical devices.
- Positive clinical trial results for companies in the portfolio.
What Are the Key Risks for SHSKX?
- Regulatory changes impacting the healthcare industry, such as drug pricing policies.
- Economic downturns leading to reduced healthcare spending.
- Competition from other health sciences funds and investment vehicles.
- Patent expirations and generic drug competition affecting pharmaceutical companies.
- Market volatility and fluctuations in the health sciences sector.
What Are the Growth Opportunities for SHSKX?
- Expansion in Emerging Markets: The increasing demand for healthcare services in emerging markets presents a significant growth opportunity for SHSKX. As these economies develop, their healthcare infrastructure improves, leading to greater adoption of advanced medical technologies and pharmaceuticals. By investing in companies that are expanding their presence in these markets, SHSKX can capitalize on this growing demand. The emerging markets healthcare sector is projected to reach $1.7 trillion by 2030, offering substantial growth potential for the fund.
- Advancements in Biotechnology: The biotechnology industry is experiencing rapid innovation, with new therapies and technologies being developed to treat a wide range of diseases. SHSKX can benefit from these advancements by investing in companies that are at the forefront of biotechnology research and development. This includes companies developing gene therapies, immunotherapies, and other cutting-edge treatments. The global biotechnology market is expected to reach $3.88 trillion by 2034, providing a significant growth opportunity for the fund.
- Growth in Healthcare Services: The healthcare services sector is also experiencing growth, driven by factors such as an aging population and increasing demand for healthcare services. SHSKX can capitalize on this growth by investing in companies that provide healthcare services, such as hospitals, clinics, and home healthcare providers. The global healthcare services market is projected to reach $13.3 trillion by 2031, offering substantial growth potential for the fund.
- Increasing Demand for Medical Devices: The medical device industry is experiencing growth, driven by technological advancements and the increasing prevalence of chronic diseases. SHSKX can benefit from this growth by investing in companies that develop and manufacture medical devices, such as diagnostic equipment, surgical instruments, and implantable devices. The global medical device market is expected to reach $850 billion by 2030, providing a significant growth opportunity for the fund.
- Strategic Acquisitions and Partnerships: Companies within the health sciences sector are increasingly engaging in strategic acquisitions and partnerships to expand their product portfolios, access new markets, and enhance their research and development capabilities. SHSKX can benefit from these activities by investing in companies that are actively pursuing strategic acquisitions and partnerships. These collaborations can lead to synergies, increased market share, and enhanced profitability for the companies involved.
What Opportunities Does SHSKX Have?
- Growth in emerging markets healthcare sectors.
- Advancements in biotechnology and pharmaceuticals.
- Increasing demand for healthcare services.
- Strategic acquisitions and partnerships within the industry.
What Threats Does SHSKX Face?
- Regulatory changes in the healthcare industry.
- Economic downturns affecting healthcare spending.
- Competition from other health sciences funds.
- Patent expirations and generic drug competition.
What Are SHSKX's Competitive Advantages?
- Established brand and reputation of BlackRock, a leading global asset manager.
- Access to BlackRock's extensive research and investment expertise.
- Concentrated investment approach allows for focused expertise in the health sciences sector.
What Does SHSKX Do?
BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX) is a non-diversified fund managed by BlackRock, Inc., a leading global investment management firm. The fund is designed to provide long-term capital growth by investing primarily in the equity securities of companies operating within the health sciences and related industries. This includes companies involved in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. The fund's investment strategy involves concentrating its assets, with at least 80% of its total assets allocated to companies in these sectors. This concentrated approach allows the fund to focus on specific areas within the health sciences industry that BlackRock believes have strong growth potential. SHSKX may also invest in companies located in non-U.S. countries, providing it with a global perspective and access to international health sciences markets. The fund's objective is to achieve long-term capital appreciation through strategic investments in the health sciences sector. As of today, March 17, 2026, the fund has a market capitalization of $5.91B, reflecting its significant presence in the asset management landscape. The fund does not distribute dividends, focusing instead on reinvesting earnings to fuel further growth. The fund maintains a beta of 0.66, indicating lower volatility compared to the broader market.
What Products and Services Does SHSKX Offer?
- Invests primarily in equity securities of companies in health sciences and related industries.
- Focuses on companies in health care equipment and supplies.
- Targets companies in health care providers and services.
- Allocates investments to companies in biotechnology.
- Includes companies in pharmaceuticals.
- Concentrates investments in health sciences or related industries.
- May invest in companies located in non-U.S. countries.
How Does SHSKX Make Money?
- Generates revenue through capital appreciation of its investments in health sciences companies.
- Focuses on long-term growth of capital by strategically allocating assets to companies with strong growth potential.
- Charges management fees based on a percentage of the fund's assets under management (AUM).
What Industry Does SHSKX Operate In?
BlackRock Health Sciences Opportunities Portfolio Class K operates within the asset management industry, specifically targeting the health sciences sector. The global healthcare market is experiencing significant growth, driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. This growth is expected to continue, creating opportunities for investment in companies within the health care equipment, biotechnology, and pharmaceutical industries. SHSKX competes with other health sciences-focused funds, such as FSPHX, LMGNX, PRPFX, RBAIX, and SHISX, each with its own investment strategy and risk profile. The competitive landscape is characterized by varying degrees of concentration, geographic focus, and investment styles.
Who Are SHSKX's Key Customers?
- Institutional investors seeking exposure to the health sciences sector.
- Individual investors looking for long-term capital growth.
- Retirement plans and other investment vehicles.
SHSKX Financials
Bull Case vs Bear Case
Bull Case
- Strong healthcare demand is a constant, making SHSKX a potentially stable long-term play.
- BlackRock's reputation often attracts investors seeking established fund managers.
- Recent insider activity might signal confidence in the fund's holdings.
- Positive community sentiment suggests growing investor belief in healthcare's growth potential.
Bear Case
- Healthcare sector faces ongoing regulatory scrutiny, creating uncertainty.
- Community discussions reveal concerns about specific holdings within the fund.
- Market perception of healthcare can shift rapidly due to policy changes.
- Recent market developments suggest investors are rotating out of defensive sectors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SHSKX Latest News
No recent news available for SHSKX.
SHSKX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SHSKX.
Price Targets
Wall Street price target analysis for SHSKX.
SHSKX MoonshotScore
What does this score mean?
The MoonshotScore rates SHSKX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
BlackRock Health Sciences Opportunities Portfolio Class K Financial Services Stock: Key Questions Answered
What does BlackRock Health Sciences Opportunities Portfolio Class K do?
BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX) is a specialized investment fund focused on achieving long-term capital growth by investing primarily in equity securities of companies operating within the health sciences and related industries. This includes companies involved in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. The fund concentrates its investments in these sectors, with a global investment scope that allows it to invest in companies located in non-U.S. countries. SHSKX aims to capitalize on the growth potential of the health sciences sector through strategic asset allocation and active management.
What are the main risks for SHSKX?
The main risks for BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX) include regulatory changes in the healthcare industry, such as drug pricing policies and healthcare reform initiatives, which can significantly impact the profitability of companies in the portfolio. Economic downturns can lead to reduced healthcare spending, affecting the demand for healthcare services and products. Competition from other health sciences funds and investment vehicles poses a risk to attracting and retaining investors. Patent expirations and generic drug competition can erode the revenue of pharmaceutical companies. Market volatility and fluctuations in the health sciences sector can also impact the fund's performance.
What are the key factors to evaluate for SHSKX?
Evaluate SHSKX on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does SHSKX data refresh on this page?
SHSKX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SHSKX's recent stock price performance?
BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong focus on the health sciences sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SHSKX overvalued or undervalued right now?
Valuing BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SHSKX?
Before investing in BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SHSKX to a portfolio?
Key strength of BlackRock Health Sciences Opportunities Portfolio Class K (SHSKX): Strong focus on the health sciences sector. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and may be subject to change.
- Investment decisions should be made based on individual risk tolerance and financial goals.